China Oncology ›› 2023, Vol. 33 ›› Issue (12): 1073-1082.doi: 10.19401/j.cnki.1007-3639.2023.12.002
• Review • Previous Articles Next Articles
WANG Xueer1(), WANG Yongsheng2()
Received:
2023-06-25
Revised:
2023-10-20
Online:
2023-12-30
Published:
2023-12-28
Contact:
WANG Yongsheng.
CLC Number:
WANG Xueer, WANG Yongsheng. The research advances and the clinical value of antibody-drug conjugate from molecular subtyping of breast cancer in the era of "precision medicine"[J]. China Oncology, 2023, 33(12): 1073-1082.
Tab. 1
The clinical application of new generation ADCs trastuzumab deruxtecan and sacituzumab govitecan in advanced/metastatic breast cancer"
Study drug | Study name | Clinical staging | HER2 status of study population | Treatment protocol/ number of lines | Primary efficacy endpoint | Safety |
---|---|---|---|---|---|---|
T-DXd | DESTINY-Breast01[ | Phase Ⅱ | Positive HER2 | T-DXd Second-line and late-line therapy | ORR: 60.9% | AE: 99.5% ≥Grade 3 AE: 57.1% |
DESTINY-Breast02[ | Phase Ⅲ | T-DXd vs capecitabine + trastuzumab/lapatinib selected by clinicians Third-line therapy | Median PFS evaluated by BICR: 17.8 months vs 6.9 months (P<0.000) | TEAE: >99% vs 95% ≥Grade 3 TEAE: 53% vs 44% | ||
DESTINY-Breast03[ | Phase Ⅲ | T-DXd vs TDM1 Second-line and late-line therapy | Median PFS evaluated by BICR: 28.8 months vs 6.8 months (P<0.000) | TEAE: >99% vs 95% ≥Grade 3 TEAE: 56% vs 52% | ||
T-DXd | DESTINY-Breast04[ | Phase Ⅲ | Low HER2 expression | T-DXd vs routine chemotherapy Second-line and late-line therapy | Median PFS: 10.1 months vs 5.4 months | AE: 99.5% vs 98.3% ≥Grade 3 AE: 52.6% vs 67.4% |
Sacituzumab govitecan | TROPiCS-02[ | Phase Ⅲ | Negative HER2 | Ditto Third-line and late-line therapy | Median PFS evaluated by BICR: 5.5 months vs 4.0 months (P=0.001) | Important ≥Grade 3 TEAE: Neutropenia: 51% vs 38% Diarrhea: 9% vs 1% |
ASCENT[ | Phase Ⅲ | Sacituzumab govitecan vs capecitabine, eribulin, vinorelbine or gemcitabine selected by clinicians Third-line and post-line therapy | Median PFS evaluated by BICR PFS: 5.6 months vs 1.7 months (P<0.001) | AE: 98% vs 86% Grade 3/4 AE: 64% vs 47% |
Tab. 2
Ongoing trials of ADCs for other molecular targets in breast cancer"
Target/study drug | Trial/study name | Clinical staging/study design | Study population | Treatment protocol | Status |
---|---|---|---|---|---|
HER3/patritumab deruxtecan(HER3-DXd, U3-1402) | NCT04610528/TOT-HER3 | Phase Ⅰ/single group assignment | HR+/HER2- early breast cancer | U3-1402 | Active, not recruiting |
Nectin4/enfortumab vedotin(EV, ASG-22CE) | NCT04225117/EV-202 | Phase Ⅱ/parallel assignment | Locally advanced or metastatic malignant solid tumors (including HR+/HER2- breast cancer; TNBC) | ASG-22CE | Active, not recruiting |
LIV-1/ladiratuzumab vedotin(SGN-LIV1A) | NCT03310957 | Phase Ⅰb, Ⅱ/single group Assignment | TNBC | SGN-LIV1A + pembrolizumab | Active, not recruiting |
ROR2/CAB-ROR2-ADC (BA3021) | NCT03504488 | Phase Ⅰ, Ⅱ/RCT | Solid tumors (including TNBC) | BA3021 vs BA3021 + PD-1 inhibitor | Recruiting |
TROP2/datopotamab deruxtecan (Dato-DXd) | NCT05460273/TROPION-PanTumor02 | Phase Ⅰ, Ⅱ/single group assignment | TNBC; NSCLC | Dato-DXd | Active, not recruiting |
TROP2/SKB264 | NCT04152499 | Phase Ⅰ, Ⅱ/sequential assignment | Advanced unresectable/metastatic solid tumors (including HR+/HER2- breast cancer; TNBC) | SKB264 | Recruiting |
Tubulin tissue factor/XB-002 | NCT04925284/JEWEL-101 | Phase Ⅰ/RCT | Advanced solid tumors (including HR+ breast cancer, TNBC) | XB-002 ± nivolumab/bevacizumab | Recruiting |
FRɑ/farletuzumab ecteribulin | NCT04300556 | Phase Ⅰ, Ⅱ/sequential assignment | Solid tumor (including TNBC) | Farletuzumab ecteribulin | Recruiting |
[1] | World Health Organization. Global cancer observatory. Estimated number of new cases in 2020, World, both sexes, all ages[EB/OL]. 2020 [2022-11-10]. https://gco.iarc.fr/today/home. |
[2] |
周昌明, 王泽洲, 郑莹. 2023年美国癌症数据解读及对中国癌症防治的启示[J]. 中国癌症杂志, 2023, 33(2): 117-125.
doi: 10.19401/j.cnki.1007-3639.2023.02.004 |
ZHOU C M, WANG Z Z, ZHENG Y. Interpretation of US cancer statistics 2023 and its implications for cancer prevention and treatment in China[J]. China Oncol, 2023, 33(2): 117-125. | |
[3] |
TARANTINO P, HAMILTON E, TOLANEY S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
doi: 10.1200/JCO.19.02488 pmid: 32330069 |
[4] |
WOLFF A C, HAMMOND M E H, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122.
doi: 10.1200/JCO.2018.77.8738 pmid: 29846122 |
[5] |
T-DXd: New standard for HER2-low breast cancer[J]. Cancer Discov, 2022, 12(8): 1828.
doi: 10.1158/2159-8290.CD-NB2022-0043 pmid: 35666611 |
[6] | 邬茜, 辛灵, 刘倩, 等. HER2低表达乳腺癌及抗体偶联药物诊治进展[J]. 中华临床医师杂志(电子版), 2021, 15(10): 735-739. |
WU Q, XIN L, LIU Q, et al. Advances in diagnosis and treatment of HER2-low breast cancer and antibody drug conjugates[J]. Chin J Clin Electron Ed, 2021, 15(10): 735-739. | |
[7] | 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040. |
The Society of Breast Cancer China Anti-Cancer Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040. | |
[8] |
JOUBERT N, BECK A, DUMONTET C, et al. Antibody-drug conjugates: the last decade[J]. Pharmaceuticals (Basel), 2020, 13(9): 245.
doi: 10.3390/ph13090245 |
[9] |
SCHLAM I, MOGES R, MORGANTI S, et al. Next-generation antibody-drug conjugates for breast cancer: moving beyond HER2 and TROP2[J]. Crit Rev Oncol Hematol, 2023, 190: 104090.
doi: 10.1016/j.critrevonc.2023.104090 |
[10] |
WANG J Y, LIU Y J, ZHANG Q Y, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies[J]. J Clin Oncol, 2021, 39(15_suppl): 1022.
doi: 10.1200/JCO.2021.39.15_suppl.1022 |
[11] |
BANYS-PALUCHOWSKI M, KRAWCZYK N, STICKELER E, et al. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023[J]. Curr Opin Obstet Gynecol, 2023, 35(1): 54-61.
doi: 10.1097/GCO.0000000000000830 |
[12] |
VON ARX C, DE PLACIDO P, CALTAVITURO A, et al. The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer[J]. Cancer Treat Rev, 2023, 113: 102500.
doi: 10.1016/j.ctrv.2022.102500 |
[13] |
MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
doi: 10.1056/NEJMoa2203690 |
[14] |
VERMA S, MILES D, GIANNI L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
doi: 10.1056/NEJMoa1209124 |
[15] |
CORTÉS J, KIM S B, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer[J]. N Engl J Med, 2022, 386(12): 1143-1154.
doi: 10.1056/NEJMoa2115022 |
[16] |
HURVITZ S A, HEGG R, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117.
doi: 10.1016/S0140-6736(22)02420-5 |
[17] |
KROP I E, KIM S B, GONZÁLEZ-MARTÍN A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15(7): 689-699.
doi: 10.1016/S1470-2045(14)70178-0 |
[18] |
EMENS L A, ESTEVA F J, BERESFORD M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol, 2020, 21(10): 1283-1295.
doi: S1470-2045(20)30465-4 pmid: 33002436 |
[19] |
HURVITZ S A, DIRIX L, KOCSIS J, et al. Phase Ⅱ randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol, 2013, 31(9): 1157-1163.
doi: 10.1200/JCO.2012.44.9694 |
[20] | National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer (version 4.2023) 2023[EB/OL]. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. |
[21] | RAMAKRISHNA N, ANDERS C K, LIN N U, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update[J]. J Clin Oncol, 2022, 40(23): 2636-2655. |
[22] |
GENNARI A, ANDRÉ F, BARRIOS C H, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer[J]. Ann Oncol, 2021, 32(12): 1475-1495.
doi: 10.1016/j.annonc.2021.09.019 pmid: 34678411 |
[23] |
BASELGA J, CORTÉS J, KIM S B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.
doi: 10.1056/NEJMoa1113216 |
[24] | PEREZ E A, BARRIOS C, EIERMANN W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase Ⅲ MARIANNE study[J]. J Clin Oncol, 2017, 35(2): 141-148. |
[25] | HURVITZ S, HEGG R, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated survival results of the randomized, phase 3 study DESTINY-Breast03[J]. Cancer Res, 2023, 83(5_Supplement): GS2-2. |
[26] |
SAURA C, OLIVEIRA M, FENG Y H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase Ⅲ NALA trial[J]. J Clin Oncol, 2020, 38(27): 3138-3149.
doi: 10.1200/JCO.20.00147 |
[27] |
MURTHY R K, LOI S, OKINES A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer[J]. N Engl J Med, 2020, 382(7): 597-609.
doi: 10.1056/NEJMoa1914609 |
[28] |
JACOBSON A. Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases[J]. Oncologist, 2022, 27(Suppl 1): S3-S4.
doi: 10.1093/oncolo/oyac009 |
[29] |
BARTSCH R, BERGHOFF A S, FURTNER J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial[J]. Nat Med, 2022, 28(9): 1840-1847.
doi: 10.1038/s41591-022-01935-8 pmid: 35941372 |
[30] |
PÉREZ-GARCÍA J M, VAZ BATISTA M, CORTEZ P, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial[J]. Neuro Oncol, 2023, 25(1): 157-166.
doi: 10.1093/neuonc/noac144 |
[31] | YAMANAKA T, NIIKURA N, NOMURA H, et al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: a multicenter retrospective study (ROSET-BM study)[J]. Cancer Res, 2023, 83(5_Supplement): PD7-1. |
[32] |
WYNN C S, TANG S C. Anti-HER2 therapy in metastatic breast cancer: many choices and future directions[J]. Cancer Metastasis Rev, 2022, 41(1): 193-209.
doi: 10.1007/s10555-022-10021-x |
[33] |
SCHETTINI F, CHIC N, BRASÓ-MARISTANY F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 1.
doi: 10.1038/s41523-020-00208-2 |
[34] |
MIGLIETTA F, GRIGUOLO G, BOTTOSSO M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 137.
doi: 10.1038/s41523-021-00343-4 |
[35] |
PEIFFER D S, ZHAO F Y, CHEN N, et al. Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database[J]. JAMA Oncol, 2023, 9(4): 500-510.
doi: 10.1001/jamaoncol.2022.7476 |
[36] | HARBECK N, MODI S N, JACOT W, et al. Trastuzumab deruxtecan vs treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer: subgroup analyses from DESTINY-Breast04[J]. Cancer Res, 2023, 83(5_Supplement): P1-11. |
[37] |
NARAYAN P, DILAWARI A, OSGOOD C, et al. US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer[J]. J Clin Oncol, 2023, 41(11): 2108-2116.
doi: 10.1200/JCO.22.02447 |
[38] |
RUGO H S, BARDIA A, MARMÉ F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2022, 40(29): 3365-3376.
doi: 10.1200/JCO.22.01002 |
[39] | KUMARI L, MISHRA L, PATEL P, et al. Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer[J]. J Drug Target, 2023: 1-19. |
[40] |
JEON Y, JO U, HONG J, et al. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer[J]. BMC Cancer, 2022, 22(1): 1014.
doi: 10.1186/s12885-022-10076-7 pmid: 36153494 |
[41] |
BARDIA A, HURVITZ S A, TOLANEY S M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541.
doi: 10.1056/NEJMoa2028485 |
[42] |
LOIBL S, LOIRAT D, TOLANEY S M, et al. Health-related quality of life in the phase Ⅲ ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer[J]. Eur J Cancer, 2023, 178: 23-33.
doi: 10.1016/j.ejca.2022.10.003 |
[43] | SPRING L, TOLANEY S, DESAI N, et al. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: results from the NeoSTAR trial[J]. J Clin Oncol, 2022, 40: 512-512. |
[44] |
JABBARZADEH KABOLI P, SHABANI S, SHARMA S, et al. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates[J]. Am J Cancer Res, 2022, 12(4): 1671-1685.
pmid: 35530278 |
[45] | BARDIA A, KROP I, MERIC-BERNSTAM F, et al. Datopotamab deruxtecan (dato-DXd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study[J]. Cancer Res, 2023, 83(5_Supplement): P6-10. |
[46] |
ANDRÉ F, HEE PARK Y, KIM S B, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 401(10390): 1773-1785.
doi: 10.1016/S0140-6736(23)00725-0 |
[47] |
DIECI M V, MIGLIETTA F, GRIGUOLO G, et al. Biomarkers for HER2-positive metastatic breast cancer: beyond hormone receptors[J]. Cancer Treat Rev, 2020, 88: 102064.
doi: 10.1016/j.ctrv.2020.102064 |
[48] |
KOYAMA K, ISHIKAWA H, ABE M, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression[J]. PLoS One, 2022, 17(5): e0267027.
doi: 10.1371/journal.pone.0267027 |
[49] | ALVES F R, GIL L, VASCONCELOS DE MATOS L, et al. Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer[J]. Cureus, 2022, 14(2): e22330. |
[50] |
TARANTINO P, JIN Q C, TAYOB N, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer[J]. JAMA Oncol, 2022, 8(8): 1177-1183.
doi: 10.1001/jamaoncol.2022.2286 pmid: 35737367 |
[51] |
CHERIFI F, DA SILVA A, JOHNSON A, et al. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer[J]. BMC Cancer, 2022, 22(1): 1081.
doi: 10.1186/s12885-022-10163-9 pmid: 36266623 |
[52] |
WOLFF A C, SOMERFIELD M R, DOWSETT M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872.
doi: 10.1200/JCO.22.02864 |
[1] | JIN Yizi, LIN Mingxi, ZHANG Jian. Receptor discordance between primary breast cancer and liver metastases [J]. China Oncology, 2023, 33(9): 834-843. |
[2] | KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui. Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer [J]. China Oncology, 2023, 33(8): 790-800. |
[3] | YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli. The specification and use of 18F-FES PET in breast cancer [J]. China Oncology, 2023, 33(8): 801-808. |
[4] | WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng. Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study [J]. China Oncology, 2023, 33(7): 686-692. |
[5] | WU Siyu, LI Junjie, SHAO Zhimin. Development history and research progress of sentinel lymph node biopsy in breast cancer [J]. China Oncology, 2023, 33(6): 551-559. |
[6] | BI Zhao, WANG Yongsheng. New concept of de-escalation management strategy in breast cancer patients with 1-2 positive sentinel lymph nodes [J]. China Oncology, 2023, 33(6): 560-565. |
[7] | ZHAO Qian, LING Yunxiao, LIU Guangyu. Recent advances and perspectives in the application of repeat sentinel lymph node biopsy in breast cancer patients underwent breast-conserving surgery [J]. China Oncology, 2023, 33(6): 566-573. |
[8] | CONG Binbin, CAO Xiaoshan, WANG Chuanjian, QIU Pengfei, SUN Xiao, CHEN Peng, LIU Yanbing, ZHAO Tong, ZHANG Zhaopeng, SHI Zhiqiang, BI Zhao, WANG Yongsheng. Feasibility analysis of sentinel lymph node biopsy in breast cancer with axilla negative evaluation by physical examination but suspicious lymph nodes finding on preoperative imaging and metastasis confirmed with biopsy [J]. China Oncology, 2023, 33(6): 574-580. |
[9] | REN Hengyu, HAO Shuang, CHEN Jiajian, YANG Benlong, CAO Ayong, LIU Guangyu, SHAO Zhimin, WU Jiong. Current status and focus of breast reconstruction research in China and abroad: a bibliometric study [J]. China Oncology, 2023, 33(6): 581-588. |
[10] | CHEN Luyan, WANG Lixue, FU Peifen. The value of surgery in the patients with de novo stage Ⅳ breast cancer [J]. China Oncology, 2023, 33(5): 431-436. |
[11] | YANG Wenxiao, GUO Linwei, LING Hong, HU Xin. Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy [J]. China Oncology, 2023, 33(5): 484-498. |
[12] | CHEN Junyao, ZHANG Wentao, LIU Qiao, NIE Jianyun. Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly [J]. China Oncology, 2023, 33(5): 506-516. |
[13] | CHEN Hong, CHEN Junxia. Effect of hsa_circ_0001573 on biological behaviors of breast cancer cells and its molecular mechanism [J]. China Oncology, 2023, 33(4): 342-353. |
[14] | BI Zhao, CHEN Peng, QIU Pengfei, CHEN Yuguang, WANG Yongsheng. The analysis of axillary lymph nodes metastasis after neoadjuvant therapy in breast cancer [J]. China Oncology, 2023, 33(4): 361-367. |
[15] | LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun. The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy [J]. China Oncology, 2023, 33(4): 377-387. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd